Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
暂无分享,去创建一个
[1] J. M. García‐Lobo,et al. First detection of the OXA-40 carbapenemase in P. aeruginosa isolates, located on a plasmid also found in A. baumannii. , 2009, Pathologie-biologie.
[2] C. Pommerenke,et al. Genomewide Identification of Genetic Determinants of Antimicrobial Drug Resistance in Pseudomonas aeruginosa , 2009, Antimicrobial Agents and Chemotherapy.
[3] P. Nordmann,et al. Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa , 2009, Antimicrobial Agents and Chemotherapy.
[4] A. Oliver,et al. β-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein , 2009, PLoS pathogens.
[5] V. Tam,et al. Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. , 2009, Diagnostic microbiology and infectious disease.
[6] P. Nordmann,et al. Further Identification of CTX-M-2 Extended-Spectrum β-Lactamase in Pseudomonas aeruginosa , 2009, Antimicrobial Agents and Chemotherapy.
[7] Iraida E. Robledo,et al. Surveillance of Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Puerto Rican Medical Center Hospitals: Dissemination of KPC and IMP-18 β-Lactamases , 2009, Antimicrobial Agents and Chemotherapy.
[8] K. Turner,et al. H-NS family members function coordinately in an opportunistic pathogen , 2008, Proceedings of the National Academy of Sciences.
[9] M. Kaufmann,et al. Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum beta-lactamases in the United Kingdom. , 2008, The Journal of antimicrobial chemotherapy.
[10] M. Galleni,et al. Role of the Ser-287-Asn Replacement in the Hydrolysis Spectrum Extension of AmpC β-Lactamases in Escherichia coli , 2008, Antimicrobial Agents and Chemotherapy.
[11] D. Wolter. Novel Mechanism of mexEF-oprN Efflux Pump Overexpression in Pseudomonas aeruginosa Without Co-Regulation of oprD Expression , 2008 .
[12] K. Poole,et al. MexCD-OprJ Multidrug Efflux System of Pseudomonas aeruginosa: Involvement in Chlorhexidine Resistance and Induction by Membrane-Damaging Agents Dependent upon the AlgU Stress Response Sigma Factor , 2008, Antimicrobial Agents and Chemotherapy.
[13] L. McIntosh,et al. The crystal structure of MexR from Pseudomonas aeruginosa in complex with its antirepressor ArmR , 2008, Proceedings of the National Academy of Sciences.
[14] R. Hancock,et al. Novel Genetic Determinants of Low-Level Aminoglycoside Resistance in Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.
[15] Robert E. W. Hancock,et al. Complex Ciprofloxacin Resistome Revealed by Screening a Pseudomonas aeruginosa Mutant Library for Altered Susceptibility , 2008, Antimicrobial Agents and Chemotherapy.
[16] A. Dinner,et al. The Pseudomonas aeruginosa multidrug efflux regulator MexR uses an oxidation-sensing mechanism , 2008, Proceedings of the National Academy of Sciences.
[17] N. Hanson,et al. Role of ampD Homologs in Overproduction of AmpC in Clinical Isolates of Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.
[18] R. Hancock,et al. Mutator Genes Giving Rise to Decreased Antibiotic Susceptibility in Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.
[19] A. Oliver,et al. Benefit of Having Multiple ampD Genes for Acquiring β-Lactam Resistance without Losing Fitness and Virulence in Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.
[20] R. Goering,et al. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] C. van Delden,et al. Resistance and Virulence of Pseudomonas aeruginosa Clinical Strains Overproducing the MexCD-OprJ Efflux Pump , 2008, Antimicrobial Agents and Chemotherapy.
[22] P. Nordmann,et al. Contribution of extended-spectrum AmpC (ESAC) beta-lactamases to carbapenem resistance in Escherichia coli. , 2008, FEMS microbiology letters.
[23] Ronald N. Jones,et al. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006). , 2007, Diagnostic microbiology and infectious disease.
[24] A. Oliver,et al. Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa Isolates from Spanish Hospitals , 2007, Antimicrobial Agents and Chemotherapy.
[25] H. Schweizer,et al. Identification and Characterization of TriABC-OpmH, a Triclosan Efflux Pump of Pseudomonas aeruginosa Requiring Two Membrane Fusion Proteins , 2007, Journal of bacteriology.
[26] H. Segal,et al. A Novel Insertion Sequence, ISPa26, in oprD of Pseudomonas aeruginosa Is Associated with Carbapenem Resistance , 2007, Antimicrobial Agents and Chemotherapy.
[27] D. Landman,et al. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. , 2007, The Journal of antimicrobial chemotherapy.
[28] M. Page,et al. Interactions of Ceftobiprole with β-Lactamases from Molecular Classes A to D , 2007, Antimicrobial Agents and Chemotherapy.
[29] D. Daigle,et al. Protein Modulator of Multidrug Efflux Gene Expression in Pseudomonas aeruginosa , 2007, Journal of bacteriology.
[30] N. Hanson,et al. Increased Expression of ampC in Pseudomonas aeruginosa Mutants Selected with Ciprofloxacin , 2007, Antimicrobial Agents and Chemotherapy.
[31] K. Perron,et al. A Copper-Activated Two-Component System Interacts with Zinc and Imipenem Resistance in Pseudomonas aeruginosa , 2007, Journal of bacteriology.
[32] Ronald N. Jones,et al. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). , 2007, Diagnostic microbiology and infectious disease.
[33] J. Quinn,et al. First Identification of Pseudomonas aeruginosa Isolates Producing a KPC-Type Carbapenem-Hydrolyzing β-Lactamase , 2007, Antimicrobial Agents and Chemotherapy.
[34] M. Page,et al. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. , 2007, Antimicrobial agents and chemotherapy.
[35] D. Paterson,et al. Coproduction of Novel 16S rRNA Methylase RmtD and Metallo-β-Lactamase SPM-1 in a Panresistant Pseudomonas aeruginosa Isolate from Brazil , 2006, Antimicrobial Agents and Chemotherapy.
[36] K. Poole,et al. nalD Encodes a Second Repressor of the mexAB-oprM Multidrug Efflux Operon of Pseudomonas aeruginosa , 2006, Journal of bacteriology.
[37] A. Robicsek,et al. Prevalence in the United States of aac(6′)-Ib-cr Encoding a Ciprofloxacin-Modifying Enzyme , 2006, Antimicrobial Agents and Chemotherapy.
[38] Neil Woodford,et al. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter , 2006 .
[39] Y. Ike,et al. Mode of Transposition and Expression of 16S rRNA Methyltransferase Gene rmtC Accompanied by ISEcp1 , 2006, Antimicrobial Agents and Chemotherapy.
[40] A. Robicsek,et al. qnr Prevalence in Ceftazidime-Resistant Enterobacteriaceae Isolates from the United States , 2006, Antimicrobial Agents and Chemotherapy.
[41] L. Piddock. Multidrug-resistance efflux pumps ? not just for resistance , 2006, Nature Reviews Microbiology.
[42] N. Hanson,et al. Model System To Evaluate the Effect of ampD Mutations on AmpC-Mediated β-Lactam Resistance , 2006, Antimicrobial Agents and Chemotherapy.
[43] W. Bilker,et al. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. , 2006, The American journal of medicine.
[44] A. Oliver,et al. Stepwise Upregulation of the Pseudomonas aeruginosa Chromosomal Cephalosporinase Conferring High-Level β-Lactam Resistance Involves Three AmpD Homologues , 2006, Antimicrobial Agents and Chemotherapy.
[45] D. Wolter,et al. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs. , 2006, The Journal of antimicrobial chemotherapy.
[46] K. Tanimoto,et al. Potency of Carbapenems for the Prevention of Carbapenem-Resistant Mutants of Pseudomonas aeruginosa , 2006, The Journal of Antibiotics.
[47] Didier Hocquet,et al. Involvement of the MexXY-OprM Efflux System in Emergence of Cefepime Resistance in Clinical Strains of Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.
[48] K. Poole,et al. Antibiotic Inducibility of the MexXY Multidrug Efflux System of Pseudomonas aeruginosa: Involvement of the Antibiotic-Inducible PA5471 Gene Product , 2006, Journal of bacteriology.
[49] J. Colmer-Hamood,et al. mvaT mutation modifies the expression of the Pseudomonas aeruginosa multidrug efflux operon mexEF-oprN. , 2006, FEMS microbiology letters.
[50] Y. Ike,et al. Novel Plasmid-Mediated 16S rRNA Methylase, RmtC, Found in a Proteus mirabilis Isolate Demonstrating Extraordinary High-Level Resistance against Various Aminoglycosides , 2006, Antimicrobial Agents and Chemotherapy.
[51] Yehuda Carmeli,et al. Multidrug-Resistant Pseudomonas aeruginosa: Risk Factors and Clinical Impact , 2006, Antimicrobial Agents and Chemotherapy.
[52] N. Woodford,et al. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. , 2006, Trends in microbiology.
[53] Marin H Kollef,et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. , 2005, Chest.
[54] C. Koh,et al. Pseudomonas aeruginosa AmpR Is a Global Transcriptional Factor That Regulates Expression of AmpC and PoxB β-Lactamases, Proteases, Quorum Sensing, and Other Virulence Factors , 2005, Antimicrobial Agents and Chemotherapy.
[55] M. Maciá,et al. Molecular Mechanisms of β-Lactam Resistance Mediated by AmpC Hyperproduction in Pseudomonas aeruginosa Clinical Strains , 2005, Antimicrobial Agents and Chemotherapy.
[56] T. Tsuchiya,et al. Gene Cloning and Properties of the RND‐Type Multidrug Efflux Pumps MexPQ‐OpmE and MexMN‐OprM from Pseudomonas aeruginosa , 2005, Microbiology and immunology.
[57] N. Hanson,et al. AmpC and OprD Are Not Involved in the Mechanism of Imipenem Hypersusceptibility among Pseudomonas aeruginosa Isolates Overexpressing the mexCD-oprJ Efflux Pump , 2005, Antimicrobial Agents and Chemotherapy.
[58] Jonathan R Edwards,et al. Overview of nosocomial infections caused by gram-negative bacilli. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[59] H. Schweizer,et al. Molecular Basis of Azithromycin-Resistant Pseudomonas aeruginosa Biofilms , 2005, Antimicrobial Agents and Chemotherapy.
[60] L. Domínguez,et al. Genetic basis for dissemination of armA. , 2005, The Journal of antimicrobial chemotherapy.
[61] Ronald N. Jones,et al. Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[62] K. Poole,et al. Induction of the MexXY Efflux Pump in Pseudomonas aeruginosa Is Dependent on Drug-Ribosome Interaction , 2005, Journal of bacteriology.
[63] P. Courvalin,et al. Worldwide Disseminated armA Aminoglycoside Resistance Methylase Gene Is Borne by Composite Transposon Tn1548 , 2005, Antimicrobial Agents and Chemotherapy.
[64] P. Nordmann,et al. Association of Plasmid-Mediated Quinolone Resistance with Extended-Spectrum β-Lactamase VEB-1 , 2005, Antimicrobial Agents and Chemotherapy.
[65] Y. Arakawa,et al. Global Spread of Multiple Aminoglycoside Resistance Genes , 2005, Emerging infectious diseases.
[66] Steven D. Brown,et al. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. , 2005, The Journal of antimicrobial chemotherapy.
[67] K. Poole,et al. Mutations in PA3574 (nalD) Lead to Increased MexAB-OprM Expression and Multidrug Resistance in Laboratory and Clinical Isolates of Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.
[68] H. Schweizer,et al. Substrate-Dependent Utilization of OprM or OpmH by the Pseudomonas aeruginosa MexJK Efflux Pump , 2005, Antimicrobial Agents and Chemotherapy.
[69] H. Schweizer,et al. Molecular Characterization of MexL, the Transcriptional Repressor of the mexJK Multidrug Efflux Operon in Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.
[70] F. Campagne,et al. Pseudomonas aeruginosa SoxR Does Not Conform to the Archetypal Paradigm for SoxR-Dependent Regulation of the Bacterial Oxidative Stress Adaptive Response , 2005, Infection and Immunity.
[71] Bong Su Kim,et al. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. , 2005, International journal of antimicrobial agents.
[72] S. Diggle,et al. The MexGHI-OpmD multidrug efflux pump controls growth, antibiotic susceptibility and virulence in Pseudomonas aeruginosa via 4-quinolone-dependent cell-to-cell communication. , 2005, Microbiology.
[73] M. Kollef,et al. Pseudomonas aeruginosa Bloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment , 2005, Antimicrobial Agents and Chemotherapy.
[74] C. Giske,et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[75] K. Poole,et al. Mutations in PA2491 (mexS) Promote MexT-Dependent mexEF-oprN Expression and Multidrug Resistance in a Clinical Strain of Pseudomonas aeruginosa , 2005, Journal of bacteriology.
[76] Ronald N. Jones,et al. Emerging epidemic of metallo-β-lactamase-mediated resistances , 2005 .
[77] K. Poole. Aminoglycoside Resistance in Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.
[78] R. Spencer. Predominant pathogens found in the European prevalence of infection in intensive care study , 1996, European Journal of Clinical Microbiology and Infectious Diseases.
[79] R. Cisterna,et al. Emergence of resistance to beta-lactam agents inPseudomonas aeruginosa with group I beta-lactamases in Spain , 1995, European Journal of Clinical Microbiology and Infectious Diseases.
[80] Ronald N. Jones,et al. Emerging epidemic of metallo-beta-lactamase-mediated resistances. , 2005, Diagnostic microbiology and infectious disease.
[81] R. MacLaren,et al. National Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002 , 2004, Antimicrobial Agents and Chemotherapy.
[82] Ronald N. Jones,et al. Molecular Characterization of a β-Lactamase Gene, blaGIM-1, Encoding a New Subclass of Metallo-β-Lactamase , 2004, Antimicrobial Agents and Chemotherapy.
[83] B. Wretlind,et al. Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[84] K. Poole,et al. MexAB‐OprM hyperexpression in NalC‐type multidrug‐resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720‐PA3719 , 2004, Molecular microbiology.
[85] A. Peleg,et al. Emergence of IMP-4 metallo-β-lactamase in a clinical isolate from Australia , 2004 .
[86] R. Goering,et al. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital. , 2004, Diagnostic microbiology and infectious disease.
[87] D. Yong,et al. Metallo-beta-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp. , 2004, Diagnostic microbiology and infectious disease.
[88] T. Nakae,et al. MexZ-mediated regulation of mexXY multidrug efflux pump expression in Pseudomonas aeruginosa by binding on the mexZ-mexX intergenic DNA. , 2004, FEMS microbiology letters.
[89] D. Livermore,et al. Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential , 2004, Antimicrobial Agents and Chemotherapy.
[90] R. Wenzel,et al. Annals of Clinical Microbiology and Antimicrobials Open Access Emerging Resistance among Bacterial Pathogens in the Intensive Care Unit – a European and North American Surveillance Study (2000–2002) Intensive-care Unitantibiotic Susceptibility , 2022 .
[91] J. Rello,et al. Patterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1,607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumonia , 2004, Intensive Care Medicine.
[92] N. Hanson,et al. Insertional inactivation ofoprD in clinical isolates ofPseudomonas aeruginosaleading to carbapenem resistance , 2004 .
[93] N. Hanson,et al. Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance. , 2004, FEMS microbiology letters.
[94] J. Karlowsky,et al. Factors Associated with Relative Rates of Antibiotic Resistance in Pseudomonas aeruginosa Isolates Tested in Clinical Laboratories in the United States from 1999 to 2002 , 2004, Antimicrobial Agents and Chemotherapy.
[95] P. Nordmann,et al. Biochemical Characterization of the Naturally Occurring Oxacillinase OXA-50 of Pseudomonas aeruginosa , 2004, Antimicrobial Agents and Chemotherapy.
[96] M. Akçay,et al. Changes of microbial flora and wound colonization in burned patients. , 2004, Burns : journal of the International Society for Burn Injuries.
[97] Ronald N. Jones,et al. Emergence of the Extended-Spectrum β-Lactamase GES-1 in a Pseudomonas aeruginosa Strain from Brazil: Report from the SENTRY Antimicrobial Surveillance Program , 2004, Antimicrobial Agents and Chemotherapy.
[98] K. Yokoyama,et al. Genetic Environments of the rmtA Gene in Pseudomonas aeruginosa Clinical Isolates , 2004, Antimicrobial Agents and Chemotherapy.
[99] T. Nakae,et al. A Quorum‐Sensing Autoinducer Enhances the mexAB‐oprM Efflux‐Pump Expression without the MexR‐Mediated Regulation in Pseudomonas aeruginosa , 2004, Microbiology and immunology.
[100] S. Diggle,et al. Biofilm Formation in Pseudomonas aeruginosa: Fimbrial cup Gene Clusters Are Controlled by the Transcriptional Regulator MvaT , 2004, Journal of bacteriology.
[101] D. Hocquet,et al. Clinical Strains of Pseudomonas aeruginosa Overproducing MexAB-OprM and MexXY Efflux Pumps Simultaneously , 2004, Antimicrobial Agents and Chemotherapy.
[102] C. Bailly,et al. Role of the Multidrug Efflux System MexXY in the Emergence of Moderate Resistance to Aminoglycosides among Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis , 2004, Antimicrobial Agents and Chemotherapy.
[103] T. Nakae,et al. Enhancement of the mexAB-oprM Efflux Pump Expression by a Quorum-Sensing Autoinducer and Its Cancellation by a Regulator, MexT, of the mexEF-oprN Efflux Pump Operon in Pseudomonas aeruginosa , 2004, Antimicrobial Agents and Chemotherapy.
[104] C. van Delden,et al. CzcR-CzcS, a Two-component System Involved in Heavy Metal and Carbapenem Resistance in Pseudomonas aeruginosa* , 2004, Journal of Biological Chemistry.
[105] P. Nordmann,et al. Resistance to Cefepime and Cefpirome Due to a 4-Amino-Acid Deletion in the Chromosome-Encoded AmpC β-Lactamase of a Serratia marcescens Clinical Isolate , 2004, Antimicrobial Agents and Chemotherapy.
[106] P. Bennett,et al. Role of the 'cre/blr-tag' DNA sequence in regulation of gene expression by the Aeromonas hydrophila beta-lactamase regulator, BlrA. , 2004, The Journal of antimicrobial chemotherapy.
[107] K. Yokoyama,et al. Plasmid-Mediated 16S rRNA Methylase in Serratia marcescens Conferring High-Level Resistance to Aminoglycosides , 2004, Antimicrobial Agents and Chemotherapy.
[108] T. Grundström,et al. Initiation of translation makes attenuation of ampC in E. coli dependent on growth rate , 2004, Molecular and General Genetics MGG.
[109] N. Caroff,et al. Detection of an IS21 insertion sequence in the mexR gene of Pseudomonas aeruginosa increasing beta-lactam resistance. , 2004, FEMS microbiology letters.
[110] A. Peleg,et al. Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia. , 2004, The Journal of antimicrobial chemotherapy.
[111] National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. , 2004, American journal of infection control.
[112] K. Yokoyama,et al. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa , 2003, The Lancet.
[113] K. Itoh,et al. Significance of Pseudomonas aeruginosa colonization of the gastrointestinal tract. , 2003, Internal medicine.
[114] T. Nakae,et al. Mutations Affecting DNA-Binding Activity of the MexR Repressor of mexR-mexA-mexB-oprM Operon Expression , 2003, Journal of bacteriology.
[115] A. Gales,et al. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. , 2003, The Journal of antimicrobial chemotherapy.
[116] K. Poole,et al. Contribution of the MexXY Multidrug Transporter to Aminoglycoside Resistance in Pseudomonas aeruginosa Clinical Isolates , 2003, Antimicrobial Agents and Chemotherapy.
[117] Y. Li,et al. A new member of the tripartite multidrug efflux pumps, MexVW-OprM, in Pseudomonas aeruginosa. , 2003, The Journal of antimicrobial chemotherapy.
[118] T. Tsuchiya,et al. Functional Cloning and Characterization of a Multidrug Efflux Pump, MexHI-OpmD, from a Pseudomonas aeruginosa Mutant , 2003, Antimicrobial Agents and Chemotherapy.
[119] P. Courvalin,et al. Plasmid-Mediated High-Level Resistance to Aminoglycosides in Enterobacteriaceae Due to 16S rRNA Methylation , 2003, Antimicrobial Agents and Chemotherapy.
[120] P. Nordmann,et al. Ambler Class A Extended-Spectrum β-Lactamases in Pseudomonas aeruginosa: Novel Developments and Clinical Impact , 2003, Antimicrobial Agents and Chemotherapy.
[121] P. Bennett,et al. Genetic linkage of the penicillinase gene, amp, and blrAB, encoding the regulator of beta-lactamase expression in Aeromonas spp. , 2003, The Journal of antimicrobial chemotherapy.
[122] J. Karlowsky,et al. Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001 , 2003, Antimicrobial Agents and Chemotherapy.
[123] J. Lucet,et al. Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit. , 2003, The Journal of hospital infection.
[124] H. Schweizer. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. , 2003, Genetics and molecular research : GMR.
[125] C. Dean,et al. Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1 , 2003, Antimicrobial Agents and Chemotherapy.
[126] G. Jacoby,et al. Prevalence of Plasmid-Mediated Quinolone Resistance , 2003, Antimicrobial Agents and Chemotherapy.
[127] D. Livermore. The threat from the pink corner , 2003, Annals of medicine.
[128] H. Oh,et al. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. , 2003, Microbial drug resistance.
[129] A. Lepape. [Epidemiology of infections due to Pseudomonas aeruginosa]. , 2003, Annales francaises d'anesthesie et de reanimation.
[130] D. Wolter,et al. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[131] A. Vanderkelen,et al. Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. , 2002, Environmental microbiology.
[132] James T. Park,et al. Substrate Specificity of the AmpG Permease Required for Recycling of Cell Wall Anhydro-Muropeptides , 2002, Journal of bacteriology.
[133] M. Hentzer,et al. Constitutive High Expression of Chromosomal β-Lactamase in Pseudomonas aeruginosa Caused by a New Insertion Sequence (IS1669) Located in ampD , 2002, Antimicrobial Agents and Chemotherapy.
[134] T. Murata,et al. Characterization of outer membrane efflux proteins OpmE, OpmD and OpmB of Pseudomonas aeruginosa: molecular cloning and development of specific antisera. , 2002, FEMS microbiology letters.
[135] Ronald N. Jones,et al. Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. , 2002, The Journal of antimicrobial chemotherapy.
[136] H. Schweizer,et al. The MexJK Efflux Pump of Pseudomonas aeruginosa Requires OprM for Antibiotic Efflux but Not for Efflux of Triclosan , 2002, Journal of bacteriology.
[137] P. Cornelis,et al. Characterization of a new efflux pump, MexGHI-OpmD, from Pseudomonas aeruginosa that confers resistance to vanadium. , 2002, Microbiology.
[138] K. Poole,et al. The MexR Repressor of the mexAB-oprM Multidrug Efflux Operon in Pseudomonas aeruginosa: Characterization of Mutations Compromising Activity , 2002, Journal of bacteriology.
[139] C. Branger,et al. Identification of PSE and OXA beta-lactamase genes in Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism. , 2002, The Journal of antimicrobial chemotherapy.
[140] H. Ohge,et al. Changes in the Intestinal Flora After the Administration of Prophylactic Antibiotics to Patients Undergoing a Gastrectomy , 2002, Surgery Today.
[141] P. Nordmann,et al. Emerging carbapenemases in Gram-negative aerobes. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[142] K. Poole. Outer membranes and efflux: the path to multidrug resistance in Gram-negative bacteria. , 2002, Current pharmaceutical biotechnology.
[143] D. Livermore,et al. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[144] Robert E W Hancock,et al. Function of pseudomonas porins in uptake and efflux. , 2002, Annual review of microbiology.
[145] A. Evangelista,et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. , 2002, International journal of antimicrobial agents.
[146] V. Miriagou,et al. An integron-associated β-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum β-lactamase IBC-1 , 2001 .
[147] C. van Delden,et al. Overexpression of the MexEF-OprN Multidrug Efflux System Affects Cell-to-Cell Signaling in Pseudomonas aeruginosa , 2001, Journal of bacteriology.
[148] T. Tsuchiya,et al. Construction of a series of mutants lacking all of the four major mex operons for multidrug efflux pumps or possessing each one of the operons from Pseudomonas aeruginosa PAO1: MexCD-OprJ is an inducible pump. , 2001, FEMS microbiology letters.
[149] A. Yamaguchi,et al. Type II Topoisomerase Mutations in Fluoroquinolone-Resistant Clinical Strains of Pseudomonas aeruginosa Isolated in 1998 and 1999: Role of Target Enzyme in Mechanism of Fluoroquinolone Resistance , 2001, Antimicrobial Agents and Chemotherapy.
[150] H. Ceri,et al. Multidrug Efflux Pumps: Expression Patterns and Contribution to Antibiotic Resistance in Pseudomonas aeruginosa Biofilms , 2001, Antimicrobial Agents and Chemotherapy.
[151] K. Poole,et al. Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. , 2001, Current topics in medicinal chemistry.
[152] P. Nordmann,et al. VEB-1-like extended-spectrum beta-lactamases in Pseudomonas aeruginosa, Kuwait. , 2001, Emerging infectious diseases.
[153] N. Masuda,et al. Hypersusceptibility of the Pseudomonas aeruginosa nfxB Mutant to β-Lactams Due to Reduced Expression of the AmpC β-Lactamase , 2001, Antimicrobial Agents and Chemotherapy.
[154] K. Poole,et al. MexR Repressor of the mexAB-oprMMultidrug Efflux Operon of Pseudomonas aeruginosa: Identification of MexR Binding Sites in the mexA-mexRIntergenic Region , 2001, Journal of bacteriology.
[155] T. Nakae,et al. Molecular mechanism of MexR-mediated regulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. , 2001, FEMS microbiology letters.
[156] G. Barnaud,et al. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. , 2001, FEMS microbiology letters.
[157] N. Gotoh,et al. Carbapenem Resistance Mechanisms in Pseudomonas aeruginosa Clinical Isolates , 2001, Antimicrobial Agents and Chemotherapy.
[158] N. Masuda,et al. Hypersusceptibility of the Pseudomonas aeruginosa nfxB mutant to beta-lactams due to reduced expression of the ampC beta-lactamase. , 2001, Antimicrobial agents and chemotherapy.
[159] V. Miriagou,et al. An integron-associated beta-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum beta-lactamase IBC-1. , 2001, The Journal of antimicrobial chemotherapy.
[160] T. Tsuchiya,et al. Roles of MexXY- and MexAB-multidrug efflux pumps in intrinsic multidrug resistance of Pseudomonas aeruginosa PAO1. , 2001, The Journal of general and applied microbiology.
[161] X. Li,et al. Influence of the MexA-MexB-oprM multidrug efflux system on expression of the MexC-MexD-oprJ and MexE-MexF-oprN multidrug efflux systems in Pseudomonas aeruginosa. , 2000, The Journal of antimicrobial chemotherapy.
[162] T. Nakae,et al. Variation of the mexT gene, a regulator of the MexEF-oprN efflux pump expression in wild-type strains of Pseudomonas aeruginosa. , 2000, FEMS microbiology letters.
[163] N. Woodford,et al. Carbapenemases: a problem in waiting? , 2000, Current opinion in microbiology.
[164] L. Piddock,et al. Two Efflux Systems Expressed Simultaneously in Multidrug-Resistant Pseudomonas aeruginosa , 2000, Antimicrobial Agents and Chemotherapy.
[165] N. Masuda,et al. Contribution of the MexX-MexY-OprM Efflux System to Intrinsic Resistance in Pseudomonas aeruginosa , 2000, Antimicrobial Agents and Chemotherapy.
[166] K. Poole. Efflux-Mediated Resistance to Fluoroquinolones in Gram-Negative Bacteria , 2000, Antimicrobial Agents and Chemotherapy.
[167] S. Lory,et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.
[168] E. Balzi,et al. Antibiotic efflux pumps. , 2000, Biochemical pharmacology.
[169] D. Hooper,et al. Mechanisms of action and resistance of older and newer fluoroquinolones. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[170] K. Poole,et al. Influence of Mutations in the mexR Repressor Gene on Expression of the MexA-MexB-OprM Multidrug Efflux System ofPseudomonas aeruginosa , 2000, Journal of bacteriology.
[171] A. Huletsky,et al. Inactivation of the ampD Gene inPseudomonas aeruginosa Leads to Moderate-Basal-Level and Hyperinducible AmpC β-Lactamase Expression , 2000, Antimicrobial Agents and Chemotherapy.
[172] N. Høiby,et al. Molecular Mechanisms of Fluoroquinolone Resistance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients , 2000, Antimicrobial Agents and Chemotherapy.
[173] M. Inoue,et al. ampR Gene Mutations That Greatly Increase Class C β-Lactamase Activity in Enterobacter cloacae , 2000, Antimicrobial Agents and Chemotherapy.
[174] E. Janas,et al. Role of Penicillin-Binding Proteins in the Initiation of the , 1999 .
[175] Nnis System,et al. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System. , 1999, American journal of infection control.
[176] D. Sherman,et al. Characterization of a Pseudomonas aeruginosa Efflux Pump Contributing to Aminoglycoside Impermeability , 1999, Antimicrobial Agents and Chemotherapy.
[177] N. Hanson,et al. Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. , 1999, Current pharmaceutical design.
[178] P. Nordmann,et al. OXA-type beta-lactamases. , 1999, Current pharmaceutical design.
[179] H. Nikaido,et al. Involvement of an Active Efflux System in the Natural Resistance of Pseudomonas aeruginosa to Aminoglycosides , 1999, Antimicrobial Agents and Chemotherapy.
[180] T. Köhler,et al. Characterization of MexT, the Regulator of the MexE-MexF-OprN Multidrug Efflux System of Pseudomonas aeruginosa , 1999, Journal of bacteriology.
[181] R. Hancock,et al. Amino Acid-Mediated Induction of the Basic Amino Acid-Specific Outer Membrane Porin OprD from Pseudomonas aeruginosa , 1999, Journal of bacteriology.
[182] Y. Carmeli,et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. , 1999, Archives of internal medicine.
[183] R. Gaynes,et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. , 1999, Critical care medicine.
[184] R. Hancock,et al. Negative Regulation of the Pseudomonas aeruginosa Outer Membrane Porin OprD Selective for Imipenem and Basic Amino Acids , 1999, Antimicrobial Agents and Chemotherapy.
[185] R. Gaynes,et al. Nosocomial Infections in Pediatric Intensive Care Units in the United States , 1999, Pediatrics.
[186] K. Poole,et al. The MexA-MexB-OprM multidrug efflux system of Pseudomonas aeruginosa is growth-phase regulated. , 1999, FEMS microbiology letters.
[187] C. Sanders,et al. Clavulanate Induces Expression of the Pseudomonas aeruginosa AmpC Cephalosporinase at Physiologically Relevant Concentrations and Antagonizes the Antibacterial Activity of Ticarcillin , 1999, Antimicrobial Agents and Chemotherapy.
[188] N. Masuda,et al. Interplay between Chromosomal β-Lactamase and the MexAB-OprM Efflux System in Intrinsic Resistance to β-Lactams inPseudomonas aeruginosa , 1999, Antimicrobial Agents and Chemotherapy.
[189] T. Takenouchi,et al. Detection of gyrA Mutations among 335Pseudomonas aeruginosa Strains Isolated in Japan and Their Susceptibilities to Fluoroquinolones , 1999, Antimicrobial Agents and Chemotherapy.
[190] T. Köhler,et al. Carbapenem Activities against Pseudomonas aeruginosa: Respective Contributions of OprD and Efflux Systems , 1999, Antimicrobial Agents and Chemotherapy.
[191] T. Tsuchiya,et al. Expression in Escherichia coli of a New Multidrug Efflux Pump, MexXY, from Pseudomonas aeruginosa , 1999, Antimicrobial Agents and Chemotherapy.
[192] V. Jarlier,et al. Type II Topoisomerase Mutations in Ciprofloxacin-Resistant Strains of Pseudomonas aeruginosa , 1999, Antimicrobial Agents and Chemotherapy.
[193] M. Bonten,et al. Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units. Implications for infection control. , 1999, American journal of respiratory and critical care medicine.
[194] N. Masuda,et al. Interplay between chromosomal beta-lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta-lactams in Pseudomonas aeruginosa. , 1999, Antimicrobial Agents and Chemotherapy.
[195] A. Huletsky,et al. An ampD Gene in Pseudomonas aeruginosa Encodes a Negative Regulator of AmpC β-Lactamase Expression , 1998, Antimicrobial Agents and Chemotherapy.
[196] B. Iglewski,et al. Cell-to-cell signaling and Pseudomonas aeruginosa infections. , 1998, Emerging infectious diseases.
[197] R. T. Villavicencio. The history of blue pus. , 1998, Journal of the American College of Surgeons.
[198] M. Tsuda,et al. Characterization of the MexC-MexD-OprJ Multidrug Efflux System in ΔmexA-mexB-oprM Mutants of Pseudomonas aeruginosa , 1998, Antimicrobial Agents and Chemotherapy.
[199] R. Hancock. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[200] K. Poole,et al. Contribution of Outer Membrane Efflux Protein OprM to Antibiotic Resistance in Pseudomonas aeruginosa Independent of MexAB , 1998, Antimicrobial Agents and Chemotherapy.
[201] Jacques Bille,et al. Frequency and molecular diversity of Pseudomonas aeruginosa upon admission and during hospitalization: a prospective epidemiologic study. , 1998, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[202] I. Paulsen,et al. Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[203] J. Höltje,et al. Growth of the Stress-Bearing and Shape-Maintaining Murein Sacculus of Escherichia coli , 1998, Microbiology and Molecular Biology Reviews.
[204] K. Poole,et al. β-Lactamase Inhibitors Are Substrates for the Multidrug Efflux Pumps of Pseudomonas aeruginosa , 1998, Antimicrobial Agents and Chemotherapy.
[205] K. Poole,et al. Expression of Pseudomonas aeruginosa Multidrug Efflux Pumps MexA-MexB-OprM and MexC-MexD-OprJ in a Multidrug-Sensitive Escherichia coli Strain , 1998, Antimicrobial Agents and Chemotherapy.
[206] S. Miyazaki,et al. In Vitro and In Vivo Antibacterial Activities of S-4661, a New Carbapenem , 1998, Antimicrobial Agents and Chemotherapy.
[207] S. Mitsuhashi,et al. Sequences of Homologous β-Lactamases from Clinical Isolates of Serratia marcescens with Different Substrate Specificities , 1998, Antimicrobial Agents and Chemotherapy.
[208] National Nosocomial Infections Surveillance (NNIS) System report, data summary from October 1986-April 1998, issued June 1998. , 1998, American journal of infection control.
[209] B. Wretlind,et al. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. , 1998, Microbial drug resistance.
[210] X. Li,et al. Inner membrane efflux components are responsible for beta-lactam specificity of multidrug efflux pumps in Pseudomonas aeruginosa , 1997, Journal of bacteriology.
[211] B. Wiedemann,et al. The signal molecule for beta-lactamase induction in Enterobacter cloacae is the anhydromuramyl-pentapeptide , 1997, Antimicrobial agents and chemotherapy.
[212] P. Nordmann,et al. OXA-18, a class D clavulanic acid-inhibited extended-spectrum beta-lactamase from Pseudomonas aeruginosa , 1997, Antimicrobial agents and chemotherapy.
[213] K. Bush,et al. Penicillin-binding proteins and induction of AmpC beta-lactamase , 1997, Antimicrobial agents and chemotherapy.
[214] N. Høiby,et al. Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different beta-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region , 1997, Antimicrobial agents and chemotherapy.
[215] J. Frère,et al. Cytosolic Intermediates for Cell Wall Biosynthesis and Degradation Control Inducible β-Lactam Resistance in Gram-Negative Bacteria , 1997, Cell.
[216] N. Gotoh,et al. Characterization of MexE–MexF–OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa , 1997, Molecular microbiology.
[217] M. Kok,et al. Multidrug efflux in intrinsic resistance to trimethoprim and sulfamethoxazole in Pseudomonas aeruginosa , 1996, Antimicrobial agents and chemotherapy.
[218] H. Nikaido. Multidrug efflux pumps of gram-negative bacteria , 1996, Journal of bacteriology.
[219] B. Wiedemann,et al. Location of N-acetylmuramyl-L-alanyl-D-glutamylmesodiaminopimelic acid, presumed signal molecule for beta-lactamase induction, in the bacterial cell , 1996, Antimicrobial agents and chemotherapy.
[220] D. Heinrichs,et al. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression , 1996, Antimicrobial agents and chemotherapy.
[221] K. Poole,et al. Overexpression of the mexC–mexD–oprJ efflux operon in nfxB‐type multidrug‐resistant strains of Pseudomonas aeruginosa , 1996, Molecular microbiology.
[222] J. Leser,et al. Sequencing and analysis of four new Enterobacter ampD Alleles , 1996, Antimicrobial agents and chemotherapy.
[223] J. García-de-Lomas,et al. Meropenem permeation through the outer membrane of Pseudomonas aeruginosa can involve pathways other than the OprD porin channel. , 1996, Chemotherapy.
[224] N. Masuda,et al. Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa , 1996, Antimicrobial agents and chemotherapy.
[225] I. Kim,et al. Affinity purification and binding characteristics of Citrobacter freundii AmpR, the transcriptional regulator of the ampC beta-lactamase gene. , 1996, Biotechnology and applied biochemistry.
[226] I. Phillips,et al. DNA sequence differences of ampD mutants of Citrobacter freundii , 1995, Antimicrobial agents and chemotherapy.
[227] K. Ishiguro,et al. Purification and Characterization of the Pseudomonas aeruginosa NfxB Protein, the Negative Regulator of the nfxB Gene , 2022 .
[228] H. Nikaido,et al. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa , 1995, Antimicrobial agents and chemotherapy.
[229] N. Masuda,et al. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa , 1995, Antimicrobial agents and chemotherapy.
[230] T. Nishino,et al. nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa , 1995, Antimicrobial agents and chemotherapy.
[231] D. Livermore,et al. Transferable production of PER-1 β-lactamase in Pseudomonas aeruginosa , 1995 .
[232] J. Frère,et al. AmpD, essential for both β‐lactamase regulation and cell wall recycling, is a novel cytosolic N‐acetylmuramyl‐L‐alanine amidase , 1995, Molecular microbiology.
[233] D. Livermore,et al. Transferable production of PER-1 beta-lactamase in Pseudomonas aeruginosa. , 1995, The Journal of antimicrobial chemotherapy.
[234] S. Normark,et al. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for beta‐lactamase induction. , 1994, The EMBO journal.
[235] J. Höltje,et al. The negative regulator of beta-lactamase induction AmpD is a N-acetyl-anhydromuramyl-L-alanine amidase. , 1994, FEMS microbiology letters.
[236] P. Nordmann,et al. Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases , 1994, Antimicrobial Agents and Chemotherapy.
[237] A. Ehrhardt,et al. β-Lactam resistance amongst Enterobacter species , 1993 .
[238] H. Yoneyama,et al. Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant Pseudomonas aeruginosa , 1993, Antimicrobial Agents and Chemotherapy.
[239] S. Normark,et al. Interactions of wild‐type and mutant AmpR of Citrobacter freundii with target DNA , 1993, Molecular microbiology.
[240] D. Heinrichs,et al. Cloning and sequence analysis of an EnvCD homologue in Pseudomonas aeruginosa: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine , 1993, Molecular microbiology.
[241] R. Gaynes,et al. An overview of nosocomial infections, including the role of the microbiology laboratory , 1993, Clinical Microbiology Reviews.
[242] C. Sanders,et al. Cefepime: the next generation? , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[243] H. H. Martin,et al. AmpG, a signal transducer in chromosomal β‐lactamase induction , 1993 .
[244] S. Busby,et al. Investigation of the Pseudomonas aeruginosa ampR gene and its role at the chromosomal ampC beta-lactamase promoter. , 1993, FEMS microbiology letters.
[245] J. Weiner,et al. Overproduction, solubilization, purification and DNA-binding properties of AmpR from Citrobacter freundii. , 1993, European journal of biochemistry.
[246] S. Lindquist,et al. Sequences of wild-type and mutant ampD genes of Citrobacter freundii and Enterobacter cloacae , 1993, Antimicrobial Agents and Chemotherapy.
[247] H. H. Martin,et al. AmpG, a signal transducer in chromosomal beta-lactamase induction. , 1993, Molecular microbiology.
[248] A. Ehrhardt,et al. beta-Lactam resistance amongst Enterobacter species. , 1993, The Journal of antimicrobial chemotherapy.
[249] D. Livermore. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa , 1992, Antimicrobial Agents and Chemotherapy.
[250] C. Sanders. beta-Lactamases of gram-negative bacteria: new challenges for new drugs. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[251] L. Piddock,et al. Selection and characterization of cefepime-resistant gram-negative bacteria. , 1991, The Journal of antimicrobial chemotherapy.
[252] H. Yoneyama,et al. Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. , 1991, The Journal of antimicrobial chemotherapy.
[253] S. Normark,et al. Purification and mutant analysis of Citrobacter freundii AmpR, the regulator for chromosomal AmpC β‐lactamase , 1991, Molecular microbiology.
[254] E. S. Moland,et al. Altered phenotypes associated with ampD mutations in Enterobacter cloacae , 1991, Antimicrobial Agents and Chemotherapy.
[255] S. Mitsuhashi,et al. Transferable imipenem resistance in Pseudomonas aeruginosa , 1991, Antimicrobial Agents and Chemotherapy.
[256] R. Hancock,et al. Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae , 1991, Antimicrobial Agents and Chemotherapy.
[257] S. Busby,et al. Cloning, sequencing and analysis of the structural gene and regulatory region of the Pseudomonas aeruginosa chromosomal ampC beta-lactamase. , 1990, The Biochemical journal.
[258] H. Nikaido,et al. Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides. , 1990, The Journal of biological chemistry.
[259] H. Nikaido,et al. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa , 1990, Antimicrobial Agents and Chemotherapy.
[260] C. Sanders,et al. Diverse potential of beta-lactamase inhibitors to induce class I enzymes , 1990, Antimicrobial Agents and Chemotherapy.
[261] H. Nikaido. Outer membrane barrier as a mechanism of antimicrobial resistance , 1989, Antimicrobial Agents and Chemotherapy.
[262] C. Sanders,et al. ampG is essential for high-level expression of AmpC beta-lactamase in Enterobacter cloacae , 1989, Antimicrobial Agents and Chemotherapy.
[263] S. Cole,et al. Regulation of enterobacterial cephalosporinase production: the role of a membrane‐bound sensory transducer , 1989, Molecular microbiology.
[264] I. Chopra,et al. Penicillin-binding protein 2 is required for induction of the Citrobacter freundii class I chromosomal beta-lactamase in Escherichia coli , 1989, Antimicrobial Agents and Chemotherapy.
[265] S. Lindquist,et al. Binding of the Citrobacter freundii AmpR regulator to a single DNA site provides both autoregulation and activation of the inducible ampC beta-lactamase gene , 1989, Journal of bacteriology.
[266] G. Drusano,et al. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa. , 1989, The Journal of antimicrobial chemotherapy.
[267] C. Sanders,et al. Heterogeneity of class I beta-lactamase expression in clinical isolates of Pseudomonas aeruginosa , 1988, Antimicrobial Agents and Chemotherapy.
[268] P. Turgeon,et al. Selection of resistance by piperacillin during Pseudomonas aeruginosa endocarditis. , 1988, The Journal of antimicrobial chemotherapy.
[269] C. Sanders,et al. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. , 1988, Reviews of infectious diseases.
[270] S. Lindquist,et al. Genetic basis of induction and overproduction of chromosomal class I beta-lactamase in nonfastidious gram-negative bacilli. , 1988, Reviews of infectious diseases.
[271] J. Quinn,et al. Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms. , 1988, Reviews of infectious diseases.
[272] J. Gatell,et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. , 1988, Reviews of infectious diseases.
[273] S. Mitsuhashi,et al. Cephalosporinase interactions and antimicrobial activity of BMY-28142, ceftazidime and cefotaxime. , 1988, The Journal of antibiotics.
[274] E. E. Stobbeeringh. Induction of chromosomal β-lactamases by different concentrations of clavulanic acid in combination with ticardillin , 1988 .
[275] E. Stobberingh. Induction of chromosomal beta-lactamases by different concentrations of clavulanic acid in combination with ticarcillin. , 1988, The Journal of antimicrobial chemotherapy.
[276] M. J. Lynch,et al. Emergence of resistance to imipenem in Pseudomonas aeruginosa , 1987, Antimicrobial Agents and Chemotherapy.
[277] R. Masterton,et al. TIMENTIN RESISTANCE , 1987, The Lancet.
[278] S. Lindquist,et al. Inactivation of the ampD gene causes semiconstitutive overproduction of the inducible Citrobacter freundii beta-lactamase , 1987, Journal of bacteriology.
[279] D. Livermore,et al. β-Lactamase Lability and Inducer Power of Newer β-Lactam Antibiotics in Relation to Their Activity Against β-Lactamase-Inducibility Mutants of Pseudomonas aeruginosa , 1987 .
[280] D. Livermore,et al. Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa. , 1987, The Journal of infectious diseases.
[281] S T Cole,et al. Inducible cephalosporinase production in clinical isolates of Enterobacter cloacae is controlled by a regulatory gene that has been deleted from Escherichia coli. , 1986, The EMBO journal.
[282] C. Sanders,et al. Type I β-Lactamases of Gram-Negative Bacteria: Interactions with β-Lactam Antibiotics , 1986 .
[283] R. Goering,et al. Evidence for multiple forms of type I chromosomal beta-lactamase in Pseudomonas aeruginosa , 1986, Antimicrobial Agents and Chemotherapy.
[284] J. Quinn,et al. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. , 1986, The Journal of infectious diseases.
[285] A. Medeiros,et al. Failure of therapy in pseudomonas endocarditis: selection of resistant mutants. , 1986, The Journal of infectious diseases.
[286] R. Labia,et al. Timentin and beta-lactamases. , 1986, The Journal of antimicrobial chemotherapy.
[287] C. Sanders,et al. Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics. , 1986, The Journal of infectious diseases.
[288] R. Labia,et al. Timentin and β-lactamases , 1986 .
[289] A. Prince,et al. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. , 1985, Reviews of infectious diseases.
[290] E. Goodell. Recycling of murein by Escherichia coli , 1985, Journal of bacteriology.
[291] S. Normark,et al. Regulatory components in Citrobacter freundii ampC beta-lactamase induction. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[292] F. Yoshimura,et al. Diffusion of beta-lactam antibiotics through the porin channels of Escherichia coli K-12 , 1985, Antimicrobial Agents and Chemotherapy.
[293] S. Levin,et al. Community-acquired Pseudomonas aeruginosa pneumonia associated with the use of a home humidifier. , 1984, The Western journal of medicine.
[294] Carle Gessard. On the Blue and Green Coloration that Appears on Bandages , 1984 .
[295] Classics in infectious diseases. On the blue and green coloration that appears on bandages. By Carle Gessard (1850-1925). , 1984, Reviews of infectious diseases.
[296] A. Chow,et al. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections , 1983, Antimicrobial Agents and Chemotherapy.
[297] C. Sanders,et al. Emergence of resistance during therapy with the newer β-lactam antibiotics: role of inducible β-lactamases and implications for the future , 1983 .
[298] C. Park,et al. Piperacillin Therapy for Pseudomonas Infections , 1983, Southern medical journal.
[299] C. Sanders,et al. Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. , 1983, Reviews of infectious diseases.
[300] John E. Bennett,et al. Principles and practices of infectious diseases , 1979 .
[301] John E. Bennett,et al. Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .
[302] T. Grundström,et al. Escherichia coli K-12 Mutants Hyperproducing Chromosomal Beta-Lactamase by Gene Repetitions , 1977, Journal of bacteriology.
[303] L. Freeman. CHRONIC GENERAL INFECTION WITH THE BACILLUS PYOCYANEUS , 1916, Annals of surgery.